pantoprazole has been researched along with Acute Pain in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Acute Pain: Intensely discomforting, distressful, or agonizing sensation associated with trauma or disease, with well-defined location, character, and timing.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Musikatavorn, K | 1 |
| Tansangngam, P | 1 |
| Lumlertgul, S | 1 |
| Komindr, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain[NCT01281501] | Phase 4 | 87 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Non-responders defined the participants who had < 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores > 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 8 |
| Pantoprazole | 11 |
"Responders define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 36 |
| Pantoprazole | 32 |
The satisfaction will be assessed by a simple, self-reported yes/no question. (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 34 |
| Pantoprazole | 34 |
"Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had <50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores > 40 millimeters were defined as Non-responders(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as Responders (good outcome)." (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | millimeter (Mean) |
|---|---|
| Conventional | 17 |
| Pantoprazole | 19 |
1 trial available for pantoprazole and Acute Pain
| Article | Year |
|---|---|
A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Pain; Adult; Anti-Ulcer Agents; Double-Blind Method; | 2012 |